Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Fox

Showing results (91-100 of 186) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2012
Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium studyYael P Mossé, Emily Lipsitz, Elizabeth Fox, et al.
Pediatric Blood & Cancer|September 23, 2010
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology GroupBrigitte C Widemann, Robert J Arceci, Nalini Jayaprakash, et al.
Cancer Chemotherapy and Pharmacology|January 2, 2010
Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumorsElizabeth Fox, John M Maris, Susan L Cohn, et al.
Cancer|April 20, 2023
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcomaKristina A Cole, Heba Ijaz, Lea F Surrey, et al.
Cancer|November 6, 2018
A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315)James I Geller, Elizabeth Fox, Brian K Turpin, et al.
Plos One|November 13, 2015
A Second Look at the Association between Gender and Mortality on Antiretroviral TherapySerena P Koenig, Alexandra Bornstein, Karine Severe, et al.
British Journal of Haematology|March 16, 2017
A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114)Susan R Rheingold, Sarah K Tasian, James A Whitlock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology groupShana Jacobs, Elizabeth Fox, Mark Krailo, et al.
Pediatric Blood & Cancer|January 8, 2024
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumorsKristy L Pilbeam, Kamnesh Pradhan, James Croop, et al.
Cold Spring Harbor Molecular Case Studies|October 28, 2022
Discovery and functional characterization of the oncogenicity and targetability of a novel <i>NOTCH1-ROS1</i> gene fusion in pediatric angiosarcomaPayal Jain, Sudarshan Iyer, Joshua Straka, et al.
Pageof 19

Showing results (91-100 of 186) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2012
Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium studyYael P Mossé, Emily Lipsitz, Elizabeth Fox, et al.
Pediatric Blood & Cancer|September 23, 2010
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology GroupBrigitte C Widemann, Robert J Arceci, Nalini Jayaprakash, et al.
Cancer Chemotherapy and Pharmacology|January 2, 2010
Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumorsElizabeth Fox, John M Maris, Susan L Cohn, et al.
Cancer|April 20, 2023
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcomaKristina A Cole, Heba Ijaz, Lea F Surrey, et al.
Cancer|November 6, 2018
A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315)James I Geller, Elizabeth Fox, Brian K Turpin, et al.
Plos One|November 13, 2015
A Second Look at the Association between Gender and Mortality on Antiretroviral TherapySerena P Koenig, Alexandra Bornstein, Karine Severe, et al.
British Journal of Haematology|March 16, 2017
A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114)Susan R Rheingold, Sarah K Tasian, James A Whitlock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology groupShana Jacobs, Elizabeth Fox, Mark Krailo, et al.
Pediatric Blood & Cancer|January 8, 2024
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumorsKristy L Pilbeam, Kamnesh Pradhan, James Croop, et al.
Cold Spring Harbor Molecular Case Studies|October 28, 2022
Discovery and functional characterization of the oncogenicity and targetability of a novel <i>NOTCH1-ROS1</i> gene fusion in pediatric angiosarcomaPayal Jain, Sudarshan Iyer, Joshua Straka, et al.
Pageof 19